| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pre-Eclampsia | 6 | 2022 | 227 | 0.910 |
Why?
|
| Infant, Premature | 7 | 2022 | 858 | 0.600 |
Why?
|
| Blood-Brain Barrier | 4 | 2019 | 157 | 0.480 |
Why?
|
| Infant, Very Low Birth Weight | 4 | 2006 | 178 | 0.480 |
Why?
|
| Fetal Blood | 2 | 2014 | 178 | 0.450 |
Why?
|
| Neonatal Screening | 3 | 2011 | 193 | 0.390 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2015 | 248 | 0.390 |
Why?
|
| Sepsis | 2 | 2011 | 519 | 0.360 |
Why?
|
| Streptococcus agalactiae | 1 | 2011 | 103 | 0.350 |
Why?
|
| Infant, Newborn | 19 | 2022 | 8623 | 0.310 |
Why?
|
| Streptococcal Infections | 1 | 2011 | 248 | 0.310 |
Why?
|
| Cocaine | 3 | 1995 | 208 | 0.300 |
Why?
|
| Pregnancy Complications | 3 | 2019 | 553 | 0.270 |
Why?
|
| Influenza Vaccines | 2 | 2023 | 497 | 0.270 |
Why?
|
| Emollients | 1 | 2006 | 2 | 0.250 |
Why?
|
| Spinal Puncture | 2 | 1996 | 53 | 0.250 |
Why?
|
| Protein Kinases | 1 | 2007 | 345 | 0.240 |
Why?
|
| Water-Electrolyte Balance | 1 | 2006 | 83 | 0.240 |
Why?
|
| Pregnancy | 16 | 2022 | 7570 | 0.240 |
Why?
|
| Syphilis, Congenital | 2 | 1996 | 30 | 0.240 |
Why?
|
| Sirolimus | 1 | 2007 | 253 | 0.240 |
Why?
|
| Influenza, Human | 2 | 2023 | 699 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2007 | 512 | 0.220 |
Why?
|
| Pericardiocentesis | 1 | 2004 | 17 | 0.220 |
Why?
|
| Infant Mortality | 2 | 1995 | 180 | 0.220 |
Why?
|
| Trophoblasts | 2 | 2015 | 119 | 0.210 |
Why?
|
| Endothelial Cells | 2 | 2019 | 544 | 0.200 |
Why?
|
| Catheterization, Central Venous | 1 | 2004 | 139 | 0.200 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2007 | 825 | 0.190 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 1995 | 243 | 0.190 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2023 | 188 | 0.180 |
Why?
|
| Case-Control Studies | 5 | 2023 | 3668 | 0.170 |
Why?
|
| Erythrocyte Transfusion | 1 | 2001 | 135 | 0.170 |
Why?
|
| Thyroxine | 1 | 2000 | 76 | 0.170 |
Why?
|
| Substance-Related Disorders | 2 | 1995 | 492 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2007 | 1356 | 0.160 |
Why?
|
| Fetal Growth Retardation | 3 | 2022 | 257 | 0.160 |
Why?
|
| Bronchopulmonary Dysplasia | 1 | 2022 | 211 | 0.160 |
Why?
|
| Diabetes, Gestational | 2 | 2017 | 115 | 0.150 |
Why?
|
| Hydrogen Peroxide | 1 | 2019 | 131 | 0.140 |
Why?
|
| Pregnancy Trimester, First | 2 | 2015 | 123 | 0.140 |
Why?
|
| Humans | 32 | 2023 | 134156 | 0.130 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 2 | 1996 | 82 | 0.130 |
Why?
|
| Database Management Systems | 1 | 2017 | 32 | 0.130 |
Why?
|
| Infant, Premature, Diseases | 3 | 2011 | 254 | 0.130 |
Why?
|
| Infant, Low Birth Weight | 2 | 1995 | 176 | 0.130 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 77 | 0.130 |
Why?
|
| Calpain | 1 | 2016 | 43 | 0.130 |
Why?
|
| Gestational Age | 4 | 2022 | 1229 | 0.130 |
Why?
|
| Infectious Disease Transmission, Vertical | 2 | 2015 | 253 | 0.130 |
Why?
|
| Pregnancy Complications, Infectious | 3 | 2015 | 486 | 0.130 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2016 | 82 | 0.130 |
Why?
|
| Female | 21 | 2022 | 71928 | 0.130 |
Why?
|
| Melatonin | 1 | 2016 | 30 | 0.120 |
Why?
|
| Toll-Like Receptors | 1 | 2016 | 85 | 0.120 |
Why?
|
| Syphilis Serodiagnosis | 1 | 1995 | 15 | 0.120 |
Why?
|
| Meningitis | 1 | 1996 | 101 | 0.120 |
Why?
|
| Chemokines | 1 | 2016 | 138 | 0.120 |
Why?
|
| Protease Inhibitors | 1 | 2016 | 100 | 0.120 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2016 | 143 | 0.120 |
Why?
|
| Quinazolines | 1 | 2016 | 185 | 0.120 |
Why?
|
| Hormones | 1 | 2016 | 198 | 0.120 |
Why?
|
| Postnatal Care | 1 | 1995 | 52 | 0.120 |
Why?
|
| Cyclic GMP-Dependent Protein Kinase Type I | 1 | 2015 | 18 | 0.120 |
Why?
|
| Renin | 1 | 2015 | 88 | 0.120 |
Why?
|
| Herpes Simplex | 1 | 2015 | 57 | 0.120 |
Why?
|
| Metabolomics | 1 | 2019 | 470 | 0.120 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 169 | 0.120 |
Why?
|
| Cyclic GMP | 1 | 2015 | 105 | 0.110 |
Why?
|
| Receptors, Artificial | 1 | 2014 | 1 | 0.110 |
Why?
|
| Thiourea | 1 | 2014 | 10 | 0.110 |
Why?
|
| Syphilis | 1 | 1995 | 98 | 0.110 |
Why?
|
| Proteomics | 1 | 2019 | 599 | 0.110 |
Why?
|
| Incidence | 3 | 2022 | 3416 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2007 | 2771 | 0.110 |
Why?
|
| Glycoproteins | 1 | 2016 | 381 | 0.110 |
Why?
|
| Caspase 3 | 1 | 2014 | 141 | 0.110 |
Why?
|
| Capillary Permeability | 1 | 2014 | 77 | 0.110 |
Why?
|
| Endothelium, Vascular | 1 | 2016 | 522 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 609 | 0.100 |
Why?
|
| Retrospective Studies | 7 | 2022 | 17540 | 0.100 |
Why?
|
| Pyrimidines | 1 | 2016 | 418 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 1995 | 182 | 0.100 |
Why?
|
| Tobacco Use Disorder | 1 | 1993 | 98 | 0.100 |
Why?
|
| Hyperglycemia | 1 | 2015 | 242 | 0.100 |
Why?
|
| Glucose | 2 | 2015 | 927 | 0.100 |
Why?
|
| Down-Regulation | 1 | 2015 | 720 | 0.100 |
Why?
|
| Receptors, Cell Surface | 1 | 2015 | 497 | 0.100 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2016 | 300 | 0.100 |
Why?
|
| Birth Weight | 3 | 2022 | 354 | 0.100 |
Why?
|
| Rats | 5 | 2019 | 3890 | 0.100 |
Why?
|
| Delivery, Obstetric | 1 | 1995 | 260 | 0.100 |
Why?
|
| Blood Cell Count | 1 | 2011 | 70 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2014 | 247 | 0.090 |
Why?
|
| Craniosynostoses | 1 | 1993 | 134 | 0.090 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2022 | 330 | 0.090 |
Why?
|
| Urine | 1 | 1991 | 92 | 0.090 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 535 | 0.090 |
Why?
|
| Cells, Cultured | 4 | 2019 | 3188 | 0.080 |
Why?
|
| Specimen Handling | 1 | 1991 | 148 | 0.080 |
Why?
|
| Seasons | 2 | 2023 | 334 | 0.080 |
Why?
|
| Adult | 8 | 2022 | 31945 | 0.080 |
Why?
|
| Risk Factors | 4 | 2022 | 11182 | 0.080 |
Why?
|
| Flow Cytometry | 2 | 2014 | 837 | 0.080 |
Why?
|
| Inflammation | 1 | 2016 | 1595 | 0.070 |
Why?
|
| Male | 10 | 2022 | 66127 | 0.070 |
Why?
|
| Reproducibility of Results | 2 | 2011 | 3043 | 0.070 |
Why?
|
| Everolimus | 1 | 2007 | 51 | 0.070 |
Why?
|
| Aromatase Inhibitors | 1 | 2007 | 79 | 0.070 |
Why?
|
| Nitriles | 1 | 2007 | 155 | 0.070 |
Why?
|
| Young Adult | 3 | 2015 | 9944 | 0.070 |
Why?
|
| Triazoles | 1 | 2007 | 142 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2011 | 2172 | 0.060 |
Why?
|
| Vaccination | 2 | 2023 | 1017 | 0.060 |
Why?
|
| Hospitalization | 1 | 1995 | 1906 | 0.060 |
Why?
|
| Administration, Topical | 1 | 2006 | 143 | 0.060 |
Why?
|
| Interleukin-1beta | 2 | 2016 | 167 | 0.060 |
Why?
|
| District of Columbia | 2 | 1995 | 17 | 0.060 |
Why?
|
| Intestinal Atresia | 1 | 2005 | 20 | 0.060 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2007 | 271 | 0.060 |
Why?
|
| Hirschsprung Disease | 1 | 2005 | 38 | 0.060 |
Why?
|
| Bilirubin | 1 | 2006 | 131 | 0.060 |
Why?
|
| Ileum | 1 | 2005 | 136 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2007 | 1140 | 0.060 |
Why?
|
| Estradiol | 1 | 2007 | 559 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2007 | 456 | 0.060 |
Why?
|
| Dimethylpolysiloxanes | 1 | 2004 | 13 | 0.060 |
Why?
|
| Silicones | 1 | 2004 | 33 | 0.060 |
Why?
|
| Prospective Studies | 2 | 2014 | 6601 | 0.060 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2004 | 113 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2019 | 1740 | 0.050 |
Why?
|
| Pericardial Effusion | 1 | 2004 | 72 | 0.050 |
Why?
|
| Infant | 4 | 2023 | 13240 | 0.050 |
Why?
|
| Influenza B virus | 1 | 2023 | 100 | 0.050 |
Why?
|
| Influenza A Virus, H3N2 Subtype | 1 | 2023 | 123 | 0.050 |
Why?
|
| Vaccines, Inactivated | 1 | 2023 | 148 | 0.050 |
Why?
|
| Pregnancy Outcome | 2 | 2016 | 629 | 0.050 |
Why?
|
| Prenatal Care | 2 | 1995 | 359 | 0.050 |
Why?
|
| Neoplasms | 1 | 2016 | 3038 | 0.040 |
Why?
|
| Deficiency Diseases | 1 | 2000 | 11 | 0.040 |
Why?
|
| Vaccination Coverage | 1 | 2021 | 37 | 0.040 |
Why?
|
| Thyroid Diseases | 1 | 2000 | 33 | 0.040 |
Why?
|
| Apoptosis | 1 | 2007 | 1946 | 0.040 |
Why?
|
| Cell Proliferation | 1 | 2007 | 2563 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2007 | 3798 | 0.040 |
Why?
|
| Cell Line | 2 | 2015 | 2864 | 0.040 |
Why?
|
| Cesarean Section | 1 | 2022 | 402 | 0.040 |
Why?
|
| Tight Junctions | 1 | 2019 | 41 | 0.040 |
Why?
|
| Outpatients | 1 | 2021 | 276 | 0.040 |
Why?
|
| Permeability | 1 | 2019 | 131 | 0.040 |
Why?
|
| Population Surveillance | 1 | 2021 | 419 | 0.040 |
Why?
|
| Animals | 5 | 2019 | 36557 | 0.030 |
Why?
|
| Logistic Models | 1 | 2022 | 1909 | 0.030 |
Why?
|
| Systole | 1 | 2017 | 206 | 0.030 |
Why?
|
| Neovascularization, Pathologic | 1 | 2019 | 263 | 0.030 |
Why?
|
| Diastole | 1 | 2017 | 185 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 2 | 2016 | 4879 | 0.030 |
Why?
|
| Aminophylline | 1 | 1996 | 8 | 0.030 |
Why?
|
| Cell Survival | 1 | 2019 | 890 | 0.030 |
Why?
|
| Cerebrospinal Fluid Proteins | 1 | 1996 | 22 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2016 | 162 | 0.030 |
Why?
|
| Wolff-Parkinson-White Syndrome | 1 | 1996 | 73 | 0.030 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2015 | 7 | 0.030 |
Why?
|
| Leukocyte Count | 1 | 1996 | 258 | 0.030 |
Why?
|
| Guanylate Cyclase | 1 | 2015 | 39 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2016 | 218 | 0.030 |
Why?
|
| Neonatal Abstinence Syndrome | 1 | 1995 | 20 | 0.030 |
Why?
|
| Intensive Care, Neonatal | 1 | 1995 | 57 | 0.030 |
Why?
|
| Cardiotonic Agents | 1 | 1996 | 144 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 399 | 0.030 |
Why?
|
| Bronchodilator Agents | 1 | 1996 | 153 | 0.030 |
Why?
|
| Hypothermia | 1 | 1995 | 64 | 0.030 |
Why?
|
| Thiazolidinediones | 1 | 2015 | 86 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2004 | 5477 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 721 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2014 | 42 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2014 | 64 | 0.030 |
Why?
|
| CD4 Antigens | 1 | 2014 | 58 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2022 | 3114 | 0.030 |
Why?
|
| Patient Admission | 1 | 1995 | 190 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2014 | 103 | 0.030 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2014 | 54 | 0.030 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2014 | 40 | 0.030 |
Why?
|
| CD3 Complex | 1 | 2014 | 93 | 0.030 |
Why?
|
| Imidazoles | 1 | 2015 | 220 | 0.030 |
Why?
|
| Brain Edema | 1 | 2014 | 71 | 0.030 |
Why?
|
| Adolescent | 3 | 2021 | 20624 | 0.030 |
Why?
|
| Pyridines | 1 | 2015 | 250 | 0.030 |
Why?
|
| Immunity, Innate | 1 | 2016 | 417 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2022 | 5222 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 1391 | 0.020 |
Why?
|
| Odds Ratio | 1 | 1995 | 1338 | 0.020 |
Why?
|
| Up-Regulation | 1 | 2015 | 915 | 0.020 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2015 | 396 | 0.020 |
Why?
|
| Signal Transduction | 2 | 2015 | 4934 | 0.020 |
Why?
|
| Research Design | 1 | 1996 | 748 | 0.020 |
Why?
|
| Premature Birth | 1 | 2016 | 418 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2014 | 446 | 0.020 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 390 | 0.020 |
Why?
|
| Infant Care | 1 | 1991 | 47 | 0.020 |
Why?
|
| Fetal Diseases | 1 | 2015 | 462 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 1765 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2014 | 1310 | 0.020 |
Why?
|
| Placenta | 1 | 2015 | 536 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 1996 | 2301 | 0.020 |
Why?
|
| Fetus | 1 | 1993 | 601 | 0.020 |
Why?
|
| Reference Values | 1 | 1991 | 741 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2021 | 7217 | 0.020 |
Why?
|
| Mice | 2 | 2016 | 19055 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3754 | 0.020 |
Why?
|
| Prevalence | 1 | 1995 | 2684 | 0.020 |
Why?
|
| Kidney | 1 | 2015 | 1421 | 0.020 |
Why?
|
| Child | 2 | 2023 | 25890 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2023 | 14884 | 0.020 |
Why?
|
| United States | 1 | 2021 | 11763 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2000 | 13074 | 0.010 |
Why?
|
| Obesity | 1 | 2016 | 2446 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2015 | 4808 | 0.010 |
Why?
|
| Aged | 1 | 2016 | 21775 | 0.010 |
Why?
|
| Theophylline | 1 | 1996 | 30 | 0.010 |
Why?
|
| Apnea | 1 | 1996 | 31 | 0.010 |
Why?
|
| Middle Aged | 1 | 2016 | 29399 | 0.010 |
Why?
|
| Electrocardiography | 1 | 1996 | 1006 | 0.010 |
Why?
|